Discontinued — last reported Q4 '25
Keysight Technologies Acquisitions decreased by 98.9% to $16.00M in Q4 2025 compared to the prior quarter. Over 4 years (FY 2021 to FY 2025), Acquisitions shows an upward trend with a 68.0% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
cf_acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $42.00M | $7.00M | $10.00M | $16.00M | $0.00 | $0.00 | $85.00M | $0.00 | $0.00 | $478.00M | $78.00M | $117.00M | $8.00M | $0.00 | $3.00M | $0.00 | $1.42B | $16.00M |
| QoQ Change | — | — | -83.3% | +42.9% | +60.0% | -100.0% | — | — | -100.0% | — | — | -83.7% | +50.0% | -93.2% | -100.0% | — | -100.0% | — | -98.9% |
| YoY Change | — | — | — | — | — | -100.0% | -100.0% | +750.0% | -100.0% | — | — | -8.2% | — | — | -100.0% | -96.2% | -100.0% | >999% | — |